Searched for
CNS THERAPEUTIC SPACE
Will the currency cycle help them? Yes, but very selectively: 10 pharma stocks with upside potential of up to 33%The biggest mistake made in currency cycles is to confuse revenue gain with pure earnings gain. A company may report stronger rupee revenue...- Possibility and probability favour them in war and peace: 10 large-cap stocks from 2 sectors with upside potential of up to 28%Probability theory is important in the stock market. Reason: Stock prices are a function of many factors and the underlying operating matri...
- Fresh tailwinds emerge as government comes in again with intent: 7 pharma stocks with upside potential of up to 36%Budget 2026 underlines the government’s intent – in terms of the sectors it will focus on. Now, it is not all of a sudden that the governme...
- Granules India gets USFDA tentative nod for generic ADHD treatment tabletsGranules Pharmaceuticals, Inc., a subsidiary of Granules India, has achieved a significant milestone with the tentative green light from US...
- Pharma stocks: Time to change the prescription? 13 pharma stocks with an upside potential of up to 39%Close to three decades back, when Indian pharma firms began to move into the US market, they faced many challenges. And the fact is that th...
- Healthcare stocks: Better to own a collection? 16 stocks from different segments with upside potential of 10 to 35% in 1 yearBefore you read on, be clear about one thing. The stocks on our list today are expensive in terms of valuations and may well witness correc...
- Dr Reddy's inks pact with Johnson & Johnson to acquire vertigo treatment brandDr. Reddy's Laboratories has finalized its acquisition of the Stugeron brand from Johnson & Johnson, encompassing EMEA regions, India, and ...
- Dr Reddy’s shares slip nearly 2% on investor concerns amid $50 million foray into anti-vertigo categoryDr. Reddy's Laboratories' shares experienced a slight dip following the announcement of their acquisition of Stugeron from Johnson & Johnso...
- Suited for the long term, even with headwinds: 8 stocks from healthcare & pharma sectors with upside potential of up to 39%How to define a “defensive sector”? One where earnings increase in a secular manner and stocks have lower probability of witnessing a sharp...
- Tailwinds and stronger balance sheets: 5 large-cap stocks with the right mix of two ratios & upside potential of up to 32%A crucial contribution to the growth of a business is the overall size of the market for its product or services. And by market size we mea...
- Corrections are opportunities, if you enter the right sector and stocks: 5 stocks from pharma sector with an upside potential of up to 32%At a time when the Nifty and Sensex are trading with cuts in excess of 1%, talking of buying stocks may not appear quite right. But correct...
- Intent of global acquisitions, has the tide turned for the long term? 5 pharma stocks with upside potential of up to 31 %Just yesterday, there was a news report which suggested that the French government is planning to block the sale of a French generic drug m...
- Sectoral tailwinds and stronger balance sheets: 5 largecap stocks with right mix of two important ratiosThere are some sectors where large players have an edge, because the nature of the business is such that there are phases where ability to ...
- 6 largecap stocks with right mix of RoE & RoCE for volatile timesEvery industry has its own operating structure, right from the raw material supply chain to who the end consumers are and what are their ne...
- Nifty healthcare index stocks; Staying bullish on select pharma and hospitalsWhile they clubbed together, the operating matrix of a pharma company making drugs and hospital and a diagnostic company are very different...
- Akums enters into a pact with Leiutis, Biophore for bringing therapeutics to IndiaThis association is set to bring succour in therapy areas of CNS disorders, pain management, and hormonal disorders, where there is a gap i...
- ZCL raises Rupees 170 cr from Morgan Stanley PEZCL said it is a speciality pharma company focusing on niche therapeutic areas of central nervous system (CNS), anti-retroviral (ARV) and c...
- Motilal Oswal PE invests Rs 40 crore in pharma company Arinna LifesciencesMotilal Oswal PE chairman Raamdeo Agrawal said Arinna, established in 2013, is a rapidly growing company in its chosen space of central ner...
- Top-five blue-chip stock picks in a volatile marketThough the market scenario is gloomy at present, some stocks can generate steady returns during all phases of an economic cycle.
- Bitter sweet: India sees 17% rise in sale of diabetic medicinesIndia, which is home to the largest diabetic population in the world, has recorded a 17% rise in the anti-diabetic drug segment.
Load More
